{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\", docket_id = \"FDA-1996-N-0006\" and posted_year = 2015 sorted by posted_date descending", "rows": [["FDA-1996-N-0006-0176", "FDA", "FDA-1996-N-0006", "Reference 9 CP1, 81N-0033 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9942"], ["FDA-1996-N-0006-0177", "FDA", "FDA-1996-N-0006", "Attachment 5 Conference Report re Comment from Merck KGaA", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9955"], ["FDA-1996-N-0006-0178", "FDA", "FDA-1996-N-0006", "Attachment 4 Review Of Over The Counter Active Ingredients re Comment from Merck KGaA", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9956"], ["FDA-1996-N-0006-0180", "FDA", "FDA-1996-N-0006", "Attachment 3 American Academy Of Dermatology, Sun Protection re Comment from Merck KGaA", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9958"], ["FDA-1996-N-0006-0179", "FDA", "FDA-1996-N-0006", "Attachment 3 Ostroff, The Bottom Line On ASIA re Comment from Merck KGaA", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9957"], ["FDA-1996-N-0006-0167", "FDA", "FDA-1996-N-0006", "Reference 4 CP1, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:48Z", null, 0, 0, "09000064804f9939"], ["FDA-1996-N-0006-0168", "FDA", "FDA-1996-N-0006", "Reference 5 CP2, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993a"], ["FDA-1996-N-0006-0166", "FDA", "FDA-1996-N-0006", "List of References re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:48Z", null, 0, 0, "09000064804f9938"], ["FDA-1996-N-0006-0170", "FDA", "FDA-1996-N-0006", "Reference 13 CP1, 95P-0145 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993c"], ["FDA-1996-N-0006-0175", "FDA", "FDA-1996-N-0006", "Reference 8 C105, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f9941"], ["FDA-1996-N-0006-0165", "FDA", "FDA-1996-N-0006", "Reference 1 PDN2, 77N-0094 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:48Z", null, 0, 0, "09000064804f9937"], ["FDA-1996-N-0006-0163", "FDA", "FDA-1996-N-0006", "Reference 3 Letter from Thomas Scarlett re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:48Z", null, 0, 0, "09000064804f9935"], ["FDA-1996-N-0006-0173", "FDA", "FDA-1996-N-0006", "Reference 10 CP1, 92P-0309 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993f"], ["FDA-1996-N-0006-0161", "FDA", "FDA-1996-N-0006", "Request for Extension from Merck KGaA & U.S. EM Industries, Inc.", "Other", "Request for Extension", "2015-07-07T04:00:00Z", 2015, 7, "2015-07-07T04:00:00Z", null, "2015-07-07T20:25:46Z", null, 0, 0, "09000064804f9965"], ["FDA-1996-N-0006-0174", "FDA", "FDA-1996-N-0006", "Reference 7 CP4, 78N-0308 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f9940"], ["FDA-1996-N-0006-0172", "FDA", "FDA-1996-N-0006", "Reference 11 CP1, 94P-0215 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993e"], ["FDA-1996-N-0006-0171", "FDA", "FDA-1996-N-0006", "Reference 12 CP2, 94P-0215 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993d"], ["FDA-1996-N-0006-0182", "FDA", "FDA-1996-N-0006", "OMB Revisions of the final Rule re Additional Criteria and Procedures for Classifying OTC Drugs as Generally Recognized as Safe and Effective and not Misbranded", "Supporting & Related Material", "Reference (internal unless indicated)", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9979"], ["FDA-1996-N-0006-0164", "FDA", "FDA-1996-N-0006", "Reference 2 Let95, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:48Z", null, 0, 0, "09000064804f9936"], ["FDA-1996-N-0006-0181", "FDA", "FDA-1996-N-0006", "Attachment 1 Letter of Authorization re Comment from Merck KGaA", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:50Z", null, 0, 0, "09000064804f9959"], ["FDA-1996-N-0006-0169", "FDA", "FDA-1996-N-0006", "Reference 6 CP3, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug", "Supporting & Related Material", "Background Material", "2015-07-07T04:00:00Z", 2015, 7, null, null, "2015-07-07T20:27:49Z", null, 0, 0, "09000064804f993b"], ["FDA-1996-N-0006-0131", "FDA", "FDA-1996-N-0006", "Letter from Personal Care Products Council and Consumer Healthcare Products Association to FDA CDER", "Other", "Letter(s)", "2015-03-20T04:00:00Z", 2015, 3, "2015-03-20T04:00:00Z", null, "2015-05-05T20:05:57Z", null, 0, 0, "0900006481a548dc"], ["FDA-1996-N-0006-0119", "FDA", "FDA-1996-N-0006", "Reference 19 - Faas et al, Female Sexual Behavior, Estrous Cycle and Gene Expression in Sexually Dimorphic Brain Regions After Pre- and Postnatal Exposure to Endocrine Active UV Filters re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:14:46Z", null, 0, 0, "0900006481a11365"], ["FDA-1996-N-0006-0124", "FDA", "FDA-1996-N-0006", "Reference 24 - Schlumpf et al, Estrogenic Activity and Estrogen Receptor Beta Binding of the UV Filter 3-Benzylidene Camphor. Comparison With 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:26:23Z", null, 0, 0, "0900006481a1137b"], ["FDA-1996-N-0006-0101", "FDA", "FDA-1996-N-0006", "Reference 1 - FDA, Guidance for industry, Photosafety Testing, May 2003 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of\r\nEnzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:09:48Z", null, 0, 0, "0900006481a11045"], ["FDA-1996-N-0006-0130", "FDA", "FDA-1996-N-0006", "Reference 30 - International Conference on Harmonization (ICH) Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies S3A, March 1995 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:58:34Z", null, 0, 0, "0900006481a1139e"], ["FDA-1996-N-0006-0104", "FDA", "FDA-1996-N-0006", "Reference 4 - Schauer, et al, Kinetics of 3-(methylbenzlidene) Camphor in Rats and Humans After Dermal Application re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:26:52Z", null, 0, 0, "0900006481a1104b"], ["FDA-1996-N-0006-0120", "FDA", "FDA-1996-N-0006", "Reference 20 - Hofkamp et al, Region-Specific Growth Effects in the Developing Rat Prostate Following Fetal Exposure to Estrogenic Ultraviolet Filters re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:16:09Z", null, 0, 0, "0900006481a11373"], ["FDA-1996-N-0006-0127", "FDA", "FDA-1996-N-0006", "Reference 27 - Guidance for Industry, S1B Testing for Carcinogenicity of Pharmaceuticals, July 1997 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:36:17Z", null, 0, 0, "0900006481a1138b"], ["FDA-1996-N-0006-0100", "FDA", "FDA-1996-N-0006", "Over-the-Counter Sunscreen Drug Products\u2014Regulatory Status of\nEnzacamene", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2015-02-25T05:00:00Z", 2015, 2, "2015-02-25T05:00:00Z", "2015-04-14T03:59:59Z", "2015-02-25T17:40:37Z", "2015-03884", 0, 0, "0900006481a16b78"], ["FDA-1996-N-0006-0128", "FDA", "FDA-1996-N-0006", "Reference 28 - International Conference on Harmonization (ICH) Guidance for Industry - S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals SIC(R2) (Revision 1), September 2008 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:38:44Z", null, 0, 0, "0900006481a1138d"], ["FDA-1996-N-0006-0113", "FDA", "FDA-1996-N-0006", "Reference 13 - Schreurs et al, Estrogenic Activity of UV Filters Determined by an In Vitro Reporter Gene Assay and an In Vivo Transgenic Zebrafish Assay re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:51:58Z", null, 0, 0, "0900006481a11349"], ["FDA-1996-N-0006-0123", "FDA", "FDA-1996-N-0006", "Reference 23 - Schlumpf et al, In Vitro and In Vivo Estrogenicity of UV Screens re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:22:10Z", null, 0, 0, "0900006481a11379"], ["FDA-1996-N-0006-0129", "FDA", "FDA-1996-N-0006", "Reference 29 - International Conference on Harmonization (ICH) Harmonized Tripartite Guideline for Industry, Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2), 2005 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:51:28Z", null, 0, 0, "0900006481a1138f"], ["FDA-1996-N-0006-0102", "FDA", "FDA-1996-N-0006", "Reference 2 - FDA, Guidance for Industry, Guideline for the Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application, February 1987 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:20:03Z", null, 0, 0, "0900006481a11047"], ["FDA-1996-N-0006-0103", "FDA", "FDA-1996-N-0006", "Reference 3 - Janjua, et al  Systemic Absorption of the Sunscreens Benzophenone-3, Octyl-Methoxycinnamate, and 3-(4-Methyl-Benzylidene) Camphor After Whole Body Topical Application and Reproductive Hormone Levels in Humans re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:22:03Z", null, 0, 0, "0900006481a11049"], ["FDA-1996-N-0006-0107", "FDA", "FDA-1996-N-0006", "Reference 7- Jimenez-Diaz et al,  Simultaneous Determination of the UV-Filters Benzyl Salicylate, Phenyl Salicylate, Octyl Salicylate, Homosalate, 3-(4-Methylbenzylidene) Camphor and 3-Benzylidene Camphor in Human Placental Tissue by LC-MS/MS. Assessment of Their In Vitro Endocrine Activity re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:41:11Z", null, 0, 0, "0900006481a11332"], ["FDA-1996-N-0006-0109", "FDA", "FDA-1996-N-0006", "Reference 9 - Ma et al,  UV Filters With Antagonistic Action at Androgen Receptors in the MDA-kb2 Cell Transcriptional-Activation Assay re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:46:34Z", null, 0, 0, "0900006481a11337"], ["FDA-1996-N-0006-0112", "FDA", "FDA-1996-N-0006", "Reference 12 - Schmutzler et al, Endocrine Disruptors and the Thyroid Gland-A Combined In Vitro and In Vivo Analysis of Potential New Biomarkers re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:50:16Z", null, 0, 0, "0900006481a11347"], ["FDA-1996-N-0006-0115", "FDA", "FDA-1996-N-0006", "Reference 15 - Soeborg et al, Risk Assessment of Topically Applied Products re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:59:57Z", null, 0, 0, "0900006481a1135d"], ["FDA-1996-N-0006-0126", "FDA", "FDA-1996-N-0006", "Reference 26 - International Conference on Harmonization (ICH), Guidance for Industry, The Need for Long Term Rodent Carcinogenicity Studies of Pharmaceuticals S1A, March 1996 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:31:30Z", null, 0, 0, "0900006481a11389"], ["FDA-1996-N-0006-0114", "FDA", "FDA-1996-N-0006", "Reference 14 - Seidlova Wuttke et al, Comparison of Effects of Estradiol With Those of Octylmethoxycinnamate and 4-Methylbenzylidene Camphor on Fat Tissue, Lipids and Pituitary Hormones re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:56:40Z", null, 0, 0, "0900006481a1134b"], ["FDA-1996-N-0006-0122", "FDA", "FDA-1996-N-0006", "Reference 22 - Maerkel et al, Sex- and Region-Specific Alterations of Progesterone Receptor mRNA Levels and Estrogen Sensitivity in Rat Brain Following Developmental Exposure to the Estrogenic UV Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:21:22Z", null, 0, 0, "0900006481a11377"], ["FDA-1996-N-0006-0117", "FDA", "FDA-1996-N-0006", "Reference 17 - Durrer et al, Estrogen Sensitivity of Target Genes and Expression of Nuclear Receptor Co-Regulators in Rat Prostate After Pre- and Postnatal Exposure to the Ultraviolet Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:09:41Z", null, 0, 0, "0900006481a11361"], ["FDA-1996-N-0006-0121", "FDA", "FDA-1996-N-0006", "Reference 21 - Maerkel et al, Sexually Dimorphic Gene Regulation in Brain as a Target for Endocrine Disrupters: Developmental Exposure of Rats to 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:19:32Z", null, 0, 0, "0900006481a11375"], ["FDA-1996-N-0006-0105", "FDA", "FDA-1996-N-0006", "Reference 5 - Janjua et al, Sunscreens in Human Plasma and Urine After Repeated Whole-Body Topical Application re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:30:38Z", null, 0, 0, "0900006481a1104d"], ["FDA-1996-N-0006-0106", "FDA", "FDA-1996-N-0006", "Reference 6 - Scientific Committee on Consumer Products (SCCP)/1184/08-SCCNFP Opinion on 4-Methylbenzylidene Camphor (4-MBC) Colipa n\u00b0 S60 Adopted During the 16th Plenary Meeting of June 24, 2008 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:37:31Z", null, 0, 0, "0900006481a11330"], ["FDA-1996-N-0006-0110", "FDA", "FDA-1996-N-0006", "Reference 10 - Mueller et al, Activation of Estrogen Receptor Alpha and ERbeta by 4-Methylbenzylidene-Camphor in Human and Rat Cells: Comparison With Phyto- and Xenoestrogens re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:47:50Z", null, 0, 0, "0900006481a11343"], ["FDA-1996-N-0006-0125", "FDA", "FDA-1996-N-0006", "Reference 25 - Schlumpf et al, Endocrine Activity and Developmental Toxicity of Cosmetic UV Filters-An Update re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:27:47Z", null, 0, 0, "0900006481a11387"], ["FDA-1996-N-0006-0108", "FDA", "FDA-1996-N-0006", "Reference 8 - Gomez et al, Estrogenic Activity of Cosmetic Components in Reporter Cell Lines:  Parabens, UV Screens and Musks re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:46:11Z", null, 0, 0, "0900006481a11335"], ["FDA-1996-N-0006-0116", "FDA", "FDA-1996-N-0006", "Reference 16 -Tinwell et al, Confirmation of Uterotrophic Activity of 3-(4-Methylbenzylidine) Camphor in the Immature Rat re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:03:10Z", null, 0, 0, "0900006481a1135f"], ["FDA-1996-N-0006-0118", "FDA", "FDA-1996-N-0006", "Reference 18 - Durrer et al, Estrogen Target Gene Regulation and Coactivator Expression in Rat Uterus After Developmental Exposure to the Ultraviolet Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T15:10:46Z", null, 0, 0, "0900006481a11363"], ["FDA-1996-N-0006-0111", "FDA", "FDA-1996-N-0006", "Reference 11 - Schlumpf et al, Estrogenic Activity and Estrogen Receptor Beta Binding of the UV Filter 3-Benzylidene Camphor. Comparison With 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene", "Supporting & Related Material", "Background Material", "2015-02-25T05:00:00Z", 2015, 2, null, null, "2015-06-22T14:48:48Z", null, 0, 0, "0900006481a11345"], ["FDA-1996-N-0006-0098", "FDA", "FDA-1996-N-0006", "Summary of Meeting Announcement from FDA CDER re FDA Implementation of the Sunscreen Innovation Act SIA February 4 2015, FDA-1996-N-0006-0097", "Supporting & Related Material", "Meeting Summary", "2015-02-23T05:00:00Z", 2015, 2, null, null, "2015-05-13T13:55:57Z", null, 0, 0, "0900006481a103e1"], ["FDA-1996-N-0006-0099", "FDA", "FDA-1996-N-0006", "Slide Presentatition from the Sunscreen Innovation Act Stakeholder Meeting re FDA Implementation of the Sunscreen Innovation Act SIA February 4 2015, FDA-1996-N-0006-0097", "Supporting & Related Material", "Meeting Materials", "2015-02-23T05:00:00Z", 2015, 2, null, null, "2015-02-23T22:19:50Z", null, 0, 0, "0900006481a1078d"], ["FDA-1996-N-0006-0097", "FDA", "FDA-1996-N-0006", "Meeting Announcement from FDA CDER re FDA Implementation of the Sunscreen Innovation Act (SIA), February 4 2015", "Other", "Memorandum", "2015-01-26T05:00:00Z", 2015, 1, "2015-01-26T05:00:00Z", null, "2015-05-05T20:00:27Z", null, 0, 0, "09000064819e06e2"]], "truncated": false, "filtered_table_rows_count": 56, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-1996-N-0006", "p2": "2015"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015", "results": [{"value": "FDA", "label": "FDA", "count": 56, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-1996-N-0006&posted_year=2015", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 52, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 3, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&document_type=Other", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015", "results": [{"value": 2015, "label": 2015, "count": 56, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1996-N-0006&posted_year=2015&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1382.1553980233148, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}